Lipodystrophies in Children
暂无分享,去创建一个
[1] B. Donadille,et al. Molecular and Cellular Bases of Lipodystrophy Syndromes , 2022, Frontiers in Endocrinology.
[2] F. Santini,et al. Autoimmunity in lipodystrophy syndromes. , 2021, Presse medicale.
[3] T. Kusakabe,et al. Practice guideline for lipodystrophy syndromes-clinically important diseases of the Japan Endocrine Society (JES). , 2021, Endocrine journal.
[4] C. Mantzoros,et al. Severe insulin resistance syndromes. , 2021, The Journal of clinical investigation.
[5] B. Knebel,et al. Lipodystrophies—Disorders of the Fatty Tissue , 2020, International journal of molecular sciences.
[6] E. Helfer,et al. Molecular and Mechanobiological Pathways Related to the Physiopathology of FPLD2 , 2020, Cells.
[7] A. Bargiota,et al. Familial Partial Lipodystrophy (FPLD): Recent Insights , 2020, Diabetes, metabolic syndrome and obesity : targets and therapy.
[8] Yingying Luo,et al. Diagnostic strategies and clinical management of lipodystrophy , 2020, Expert review of endocrinology & metabolism.
[9] B. Akıncı,et al. Current Diagnosis, Treatment and Clinical Challenges in the Management of Lipodystrophy Syndromes in Children and Young People , 2020, Journal of clinical research in pediatric endocrinology.
[10] C. Vigouroux,et al. Lipodystrophic syndromes: From diagnosis to treatment. , 2019, Annales d'endocrinologie.
[11] Feng-Jung Chen,et al. CIDE family proteins control lipid homeostasis and the development of metabolic diseases , 2019, Traffic.
[12] C. Vigouroux,et al. Diagnostic Challenge in PLIN1-Associated Familial Partial Lipodystrophy , 2019, The Journal of clinical endocrinology and metabolism.
[13] D. Savage,et al. Recent developments in lipodystrophy. , 2019, Current opinion in lipidology.
[14] E. Kalkhoven,et al. Gene-gene and gene-environment interactions in lipodystrophy: Lessons learned from natural PPARγ mutants. , 2019, Biochimica et biophysica acta. Molecular and cell biology of lipids.
[15] E. Deeks. Metreleptin in lipodystrophy: a profile of its use , 2019, Drugs & Therapy Perspectives.
[16] V. Saudek,et al. Dual binding motifs underpin the hierarchical association of perilipins1–3 with lipid droplets , 2019, Molecular biology of the cell.
[17] M. Weedon,et al. PLIN1 Haploinsufficiency Is Not Associated With Lipodystrophy , 2018, The Journal of clinical endocrinology and metabolism.
[18] S. O’Rahilly,et al. Genetic syndromes of severe insulin resistance. , 2018, Current opinion in genetics & development.
[19] F. Santini,et al. Diagnosis and treatment of lipodystrophy: a step-by-step approach , 2018, Journal of Endocrinological Investigation.
[20] J. Seissler,et al. Insulin secretory defect in familial partial lipodystrophy Type 2 and successful long‐term treatment with a glucagon‐like peptide 1 receptor agonist , 2017, Diabetic medicine : a journal of the British Diabetic Association.
[21] C. Mantzoros,et al. Adipose tissue and reproductive health. , 2017, Metabolism: clinical and experimental.
[22] E. Chiquette,et al. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges , 2017, Diabetes, metabolic syndrome and obesity : targets and therapy.
[23] Robert V Farese,et al. Lipid Droplet Biogenesis. , 2017, Annual review of cell and developmental biology.
[24] F. Rubino,et al. Roux-en-Y Gastric Bypass Surgery in the Management of Familial Partial Lipodystrophy Type 1 , 2017, The Journal of clinical endocrinology and metabolism.
[25] A. Tsatsoulis,et al. Familial partial lipodystrophy and proteinuric renal disease due to a missense c.1045C > T LMNA mutation , 2017, Endocrinology, diabetes & metabolism case reports.
[26] K. Muroya,et al. Partial lipodystrophy in patients who have undergone hematopoietic stem cell transplantation during childhood: an institutional cross-sectional survey , 2017, Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology.
[27] M. Kroh,et al. Successful Treatment of an Unusual Case of FPLD2: The Role of Roux-en-Y Gastric Bypass—Case Report and Literature Review , 2017, Journal of Gastrointestinal Surgery.
[28] F. Karpe,et al. What have human experimental overfeeding studies taught us about adipose tissue expansion and susceptibility to obesity and metabolic complications? , 2017, International Journal of Obesity.
[29] A. Garg,et al. Homozygous LIPE mutation in siblings with multiple symmetric lipomatosis, partial lipodystrophy, and myopathy , 2017, American journal of medical genetics. Part A.
[30] Inês Barroso,et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance , 2016, Nature Genetics.
[31] D. Dunger,et al. The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline , 2016, The Journal of clinical endocrinology and metabolism.
[32] E. Oral,et al. Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program , 2016, Journal of diabetes & metabolism.
[33] E. Jaffe,et al. Lymphoma in acquired generalized lipodystrophy , 2016, Leukemia & lymphoma.
[34] N. Patni,et al. Congenital generalized lipodystrophies—new insights into metabolic dysfunction , 2015, Nature Reviews Endocrinology.
[35] T. Atik,et al. Acquired partial lipodystrophy is associated with increased risk for developing metabolic abnormalities. , 2015, Metabolism: clinical and experimental.
[36] V. Cortés,et al. Lipodystrophies: adipose tissue disorders with severe metabolic implications , 2015, Journal of Physiology and Biochemistry.
[37] C. Vigouroux,et al. Metabolic and cardiac phenotype characterization in 37 atypical Dunnigan patients with nonfarnesylated mutated prelamin A. , 2015, American heart journal.
[38] P. Gorden,et al. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. , 2015, The Journal of clinical endocrinology and metabolism.
[39] Q. Gao,et al. Seipin performs dissectible functions in promoting lipid droplet biogenesis and regulating droplet morphology , 2015, Molecular biology of the cell.
[40] M. Glesby,et al. HIV/AIDS and lipodystrophy: Implications for clinical management in resource-limited settings , 2015, Journal of the International AIDS Society.
[41] E. Ravussin,et al. Caveolin-1 Expression and Cavin Stability Regulate Caveolae Dynamics in Adipocyte Lipid Store Fluctuation , 2014, Diabetes.
[42] J. Moreno-Navarrete,et al. Polymerase I and transcript release factor (PTRF) regulates adipocyte differentiation and determines adipose tissue expandability , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[43] K. Rother,et al. Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy. , 2014, The Journal of clinical endocrinology and metabolism.
[44] S. Baig,et al. Exome sequencing circumvents missing clinical data and identifies a BSCL2 mutation in congenital lipodystrophy , 2014, BMC Medical Genetics.
[45] Jeffrey R O'Connell,et al. Null mutation in hormone-sensitive lipase gene and risk of type 2 diabetes. , 2014, The New England journal of medicine.
[46] A. Ciccodicola,et al. PPARG in Human Adipogenesis: Differential Contribution of Canonical Transcripts and Dominant Negative Isoforms , 2014, PPAR research.
[47] Y. Sakamoto,et al. Severe congenital lipodystrophy and a progeroid appearance: Mutation in the penultimate exon of FBN1 causing a recognizable phenotype , 2013, American journal of medical genetics. Part A.
[48] T. Nolis. Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies , 2013, Journal of Human Genetics.
[49] D. Carvalho,et al. Lipodystrophy: beyond generalization? , 2013, Panminerva medica.
[50] Sahar Mansour,et al. Mutations in PIK3R1 cause SHORT syndrome. , 2013, American journal of human genetics.
[51] Stefan Johansson,et al. SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling. , 2013, American journal of human genetics.
[52] Patrick Callier,et al. PIK3R1 mutations cause syndromic insulin resistance with lipoatrophy. , 2013, American journal of human genetics.
[53] B. Venkatesh,et al. Seipin differentially regulates lipogenesis and adipogenesis through a conserved core sequence and an evolutionarily acquired C-terminus. , 2013, The Biochemical journal.
[54] J. Chan,et al. The clinical approach to the detection of lipodystrophy - an AACE consensus statement. , 2013, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[55] Charles R. Evans,et al. Alterations in lipid signaling underlie lipodystrophy secondary to AGPAT2 mutations. Diabetes 2012;61:2922–2931 , 2013, Diabetes.
[56] S. O’Rahilly,et al. The human lipodystrophy protein seipin is an ER membrane adaptor for the adipogenic PA phosphatase lipin 1. , 2013, Molecular metabolism.
[57] Charles R. Evans,et al. Alterations in Lipid Signaling Underlie Lipodystrophy Secondary to AGPAT2 Mutations , 2012, Diabetes.
[58] R. Payne. Cardiovascular risk. , 2012, British journal of clinical pharmacology.
[59] A. Agarwal. Lysophospholipid acyltransferases: 1-acylglycerol-3-phosphate O-acyltransferases. From discovery to disease , 2012, Current opinion in lipidology.
[60] J. Goodman,et al. Seipin: from human disease to molecular mechanism , 2012, Journal of Lipid Research.
[61] P. Gorden,et al. Pregnancy in a Woman With Congenital Generalized Lipodystrophy: Leptin's Vital Role in Reproduction , 2012, Obstetrics and gynecology.
[62] J. Chan,et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[63] A. Lecube,et al. Successful treatment for the Dunnigan‐type familial partial lipodystrophy with Roux‐en‐Y gastric bypass , 2011, Clinical endocrinology.
[64] C. Vigouroux,et al. Molecular mechanisms of human lipodystrophies: from adipocyte lipid droplet to oxidative stress and lipotoxicity. , 2011, The international journal of biochemistry & cell biology.
[65] S. O’Rahilly,et al. Perilipin deficiency and autosomal dominant partial lipodystrophy. , 2011, The New England journal of medicine.
[66] S. O’Rahilly,et al. Lipodystrophy: metabolic insights from a rare disorder. , 2010, The Journal of endocrinology.
[67] M. Delgado,et al. Congenital generalized lipodystrophy, type 4 (CGL4) associated with myopathy due to novel PTRF mutations , 2010, American journal of medical genetics. Part A.
[68] J. Chan,et al. Clinical classification and treatment of congenital and acquired lipodystrophy. , 2010, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[69] D. Seelow,et al. Fatal Cardiac Arrhythmia and Long-QT Syndrome in a New Form of Congenital Generalized Lipodystrophy with Muscle Rippling (CGL4) Due to PTRF-CAVIN Mutations , 2010, PLoS genetics.
[70] L. Subramanyam,et al. Overlapping syndrome with familial partial lipodystrophy, Dunnigan variety and cardiomyopathy due to amino‐terminal heterozygous missense lamin A/C mutations , 2009, Clinical genetics.
[71] S. Bernasconi,et al. Mandibuloacral dysplasia type A in childhood , 2009, American journal of medical genetics. Part A.
[72] Cristina T Fonseca,et al. Novel mutations of the BSCL2 and AGPAT2 genes in 10 families with Berardinelli–Seip congenital generalized lipodystrophy syndrome , 2009, Clinical endocrinology.
[73] A. Garg,et al. Inherited lipodystrophies and hypertriglyceridemia , 2009, Current opinion in lipidology.
[74] S. O’Rahilly,et al. Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC , 2009, EMBO molecular medicine.
[75] L. Tavazzi,et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. , 2008, Journal of the American College of Cardiology.
[76] A. K. Agarwal,et al. Novel subtype of congenital generalized lipodystrophy associated with muscular weakness and cervical spine instability , 2008, American journal of medical genetics. Part A.
[77] S. O’Rahilly,et al. The Human Lipodystrophy Gene BSCL2/Seipin May Be Essential for Normal Adipocyte Differentiation , 2008, Diabetes.
[78] S. O’Rahilly,et al. Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. , 2008, The Journal of clinical endocrinology and metabolism.
[79] P. Pilch,et al. A Critical Role of Cavin (Polymerase I and Transcript Release Factor) in Caveolae Formation and Organization* , 2008, Journal of Biological Chemistry.
[80] S. Kanazawa,et al. Computed tomography findings of congenital generalized lipodystrophy: multiple nodular fatty liver and diffuse sclerosis of bones , 2007, Radiation Medicine.
[81] R. Parton,et al. The multiple faces of caveolae , 2007, Nature Reviews Molecular Cell Biology.
[82] Xianlin Han,et al. A Regulatory Role for 1-Acylglycerol-3-phosphate-O-acyltransferase 2 in Adipocyte Differentiation* , 2006, Journal of Biological Chemistry.
[83] J. Pinkney,et al. Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C , 2005, Diabetologia.
[84] G. Behrens. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. , 2005, The New England journal of medicine.
[85] P. Vermersch,et al. Patients with familial partial lipodystrophy of the Dunnigan type due to a LMNA R482W mutation show muscular and cardiac abnormalities. , 2004, The Journal of clinical endocrinology and metabolism.
[86] S. O’Rahilly,et al. Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. , 2004, The Journal of clinical endocrinology and metabolism.
[87] A. Kimmel,et al. The Central Role of Perilipin A in Lipid Metabolism and Adipocyte Lipolysis , 2004, IUBMB life.
[88] A. Garg. Acquired and inherited lipodystrophies. , 2004, The New England journal of medicine.
[89] A. Garg,et al. Clinical Features and Metabolic and Autoimmune Derangements in Acquired Partial Lipodystrophy: Report of 35 Cases and Review of the Literature , 2004, Medicine.
[90] A. Garg,et al. Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2 or seipin genes. , 2003, The Journal of clinical endocrinology and metabolism.
[91] A. K. Agarwal,et al. Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. , 2003, Human molecular genetics.
[92] A. Garg,et al. Congenital generalized lipodystrophy: significance of triglyceride biosynthetic pathways , 2003, Trends in Endocrinology & Metabolism.
[93] A. Chait,et al. Köbberling type of familial partial lipodystrophy: an underrecognized syndrome. , 2003, Diabetes care.
[94] Laura Scott,et al. Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome , 2003, Nature.
[95] A. Garg,et al. Clinical Features and Metabolic Derangements in Acquired Generalized Lipodystrophy: Case Reports and Review of the Literature , 2003, Medicine.
[96] A. Garg,et al. Lipodystrophy in Human Immunodeficiency Virus-Infected Patients , 2002 .
[97] S. O’Rahilly,et al. Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy , 2002, Journal of medical genetics.
[98] G. Scarano,et al. Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. , 2002, American journal of human genetics.
[99] M. Serrano-Ríos,et al. Leptin and Adipose Tissue Maldistribution in HIV‐Infected Male Patients With Predominant Fat Loss Treated With Antiretroviral Therapy , 2002, Journal of acquired immune deficiency syndromes.
[100] J. Engelman,et al. Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav‐1, ‐2, and ‐3) , 1998, FEBS letters.
[101] S. O’Rahilly,et al. Impaired activation of phosphoinositide 3-kinase by insulin in fibroblasts from patients with severe insulin resistance and pseudoacromegaly. A disorder characterized by selective postreceptor insulin resistance. , 1998, The Journal of clinical investigation.
[102] O. Trygstad,et al. Generalized lipodystrophy, congenital and acquired (lipoatrophy) , 1996, Acta paediatrica (Oslo, Norway : 1992). Supplement.
[103] J. Köbberling,et al. Familial partial lipodystrophy: two types of an X linked dominant syndrome, lethal in the hemizygous state. , 1986, Journal of medical genetics.
[104] M. Seip. Lipodystrophy and gigantism with associated endocrine manifestations. A new diencephalic syndrome? , 1959, Acta paediatrica.
[105] W. Berardinelli. An undiagnosed endocrinometabolic syndrome: report of 2 cases. , 1954, The Journal of clinical endocrinology and metabolism.
[106] M. Kurusz,et al. Efficacy and safety , 2021, Perfusion.
[107] A. Garg,et al. Lipodystrophy Syndromes. , 2016, Endocrinology and metabolism clinics of North America.
[108] C. Mantzoros,et al. Leptin in congenital and HIV-associated lipodystrophy. , 2015, Metabolism: clinical and experimental.
[109] C. Mantzoros,et al. From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. , 2015, Metabolism: clinical and experimental.
[110] A. Garg. Lipodystrophies: Genetic and Acquired Body Fat Disorders , 2011 .
[111] E. Mesquita,et al. [Cardiometabolic abnormalities in patients with Berardinelli-Seip syndrome]. , 2010, Arquivos brasileiros de cardiologia.
[112] Kenneth G. C. Smith,et al. Complement abnormalities in acquired lipodystrophy revisited. , 2009, The Journal of clinical endocrinology and metabolism.
[113] N. Maraldi,et al. Implications for nuclear organization and gene transcription of lamin A/C specific mutations. , 2005, Advances in enzyme regulation.
[114] A. Bowcock,et al. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34 , 2002, Nature Genetics.
[115] A. Garg,et al. A Novel Heterozygous Mutation in Peroxisome Proliferator-Activated Receptor-γ Gene in a Patient with Familial Partial Lipodystrophy , 2002 .
[116] R. Hegele,et al. Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy. , 2000, Human molecular genetics.
[117] R. Peshock,et al. Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety). , 1999, The Journal of clinical endocrinology and metabolism.